Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 5-year average of 2.30%, near the low end of its 5-year range (0.00%–70.39%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
2.30%
GROSS MARGIN AVG 10Y
7.57%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Market Cap
$7.08M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.90M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
4.26%
5Y Avg
4.26%
Market Cap
$7.31M
Gross Margin
14.92%
TTM Avg
28.44%
3Y Avg
28.69%
5Y Avg
27.44%
Market Cap
$7.00M
Gross Margin
54.43%
TTM Avg
58.30%
3Y Avg
57.46%
5Y Avg
45.97%
Market Cap
$6.99M
Gross Margin
80.62%
TTM Avg
90.31%
3Y Avg
-419.28%
5Y Avg
-4158.68%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| KALA BIO, Inc. (KALA) | $7.09M | 0.00% | 0.00% | 0.00% | 2.30% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | 0.00% | 0.00% | 0.00% | 0.00% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $6.90M | 0.00% | 0.00% | 4.26% | 4.26% |
| Longeveron Inc. (LGVN)vs › | $7.27M | 69.76% | 72.87% | 54.39% | 49.20% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | 14.92% | 28.44% | 28.69% | 27.44% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.00M | 54.43% | 58.30% | 57.46% | 45.97% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.99M | 80.62% | 90.31% | -419.28% | -4158.68% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.40M | 0.00% | 0.00% | 0.00% | 0.00% |
| Exicure, Inc. (XCUR)vs › | $6.82M | 0.00% | 50.00% | 48.39% | 33.40% |
| Aclarion, Inc. (ACON)vs › | $6.72M | -291.27% | -237.54% | -120.88% | -89.07% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 57.14% |
| 2022-06-30 | 15.52% |
| 2022-03-31 | 43.51% |
| 2021-12-31 | 23.60% |
| 2021-09-30 | 70.39% |
| 2021-06-30 | 66.70% |
| 2021-03-31 | 69.29% |
| 2020-12-31 | 29.22% |
| 2020-09-30 | 59.10% |
| 2020-06-30 | -75.51% |
| 2020-03-31 | 1.31% |
| 2019-12-31 | 17.37% |
| 2019-09-30 | 38.39% |
| 2019-06-30 | 82.89% |
| 2019-03-31 | 38.82% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
